electroCore (NASDAQ:ECOR) Announces Quarterly Earnings Results

Key Points

• Beat expectations and record quarter: electroCore reported EPS of $0.37 vs. consensus ($0.59) and record revenue of $9.6M (+43% YoY) with an 87% gross margin and an improved adjusted EBITDA loss of $2.3M, which management says shows emerging operating leverage.
• VA growth and clinical catalysts: prescription device revenue rose 48% with ~15,000 VA patients (~2.5% penetration), and management is pursuing expanded indications for PTSD backed by Breakthrough Device designation and the ongoing Acacia trial.
• Cash burn and financing risk: cash fell to about $8.8M from $11.6M, GAAP net loss widened to $5.3M (including $1.9M one‑time transition costs), and management is evaluating capital-raising options.

electroCore (NASDAQ:ECOR - Get Free Report) posted its earnings results on Wednesday. The company reported $0.37 earnings per share for the quarter, topping the consensus estimate of ($0.59) by $0.96, FiscalAI reports. The company had revenue of $9.58 million for the quarter, compared to analyst estimates of $9.01 million. electroCore had a negative net margin of 43.60% and a negative return on equity of 1,956.38%.

Here are the key takeaways from electroCore's conference call:

• Record quarter — $9.6M revenue (+43% YoY) with an 87% gross margin and a 24% improvement in adjusted EBITDA loss to $2.3M, which management cites as evidence of emerging operating leverage.
• The VA remains the largest growth driver — prescription device revenue rose 48% and ~15,000 VA patients have received devices (estimated ~2.5% penetration), signaling substantial upside as the new COO focuses on increasing per-site utilization.
• Clinical and regulatory catalysts could expand indications — PTSD has Breakthrough Device designation, Acacia trial enrollment is underway, and recent publications support NVNS benefits, which management plans to aggregate for a potential PTSD label.
• Consumer channel momentum — Truvaga revenue was ~$1.5M (+38% YoY) with improved ROAS (~2.37) and a January U.K. soft launch, while next‑gen mobile features are being developed to pursue recurring revenue.
• Cash and profitability pressure — cash and equivalents fell to ~$8.8M from $11.6M, Q1 was the company’s highest burn quarter, GAAP net loss widened to $5.3M (including $1.9M one‑time transition costs), and management is evaluating capital options.

electroCore Price Performance

ECOR traded down $0.33 during mid-day trading on Wednesday, hitting $6.66. The stock had a trading volume of 18,881 shares, compared to its average volume of 58,523. The stock's fifty day simple moving average is $6.60 and its 200-day simple moving average is $5.87. electroCore has a 1-year low of $4.16 and a 1-year high of $8.64. The firm has a market capitalization of $53.81 million, a price-to-earnings ratio of -4.04 and a beta of 0.68.

Insider Activity

In other news, Director Daniel S. Goldberger sold 16,072 shares of the stock in a transaction on Friday, April 10th. The shares were sold at an average price of $6.02, for a total transaction of $96,753.44. Following the completion of the sale, the director owned 291,471 shares of the company's stock, valued at $1,754,655.42. This represents a 5.23% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 13.80% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On electroCore

Several large investors have recently made changes to their positions in the stock. Two Sigma Investments LP increased its position in shares of electroCore by 20.8% during the third quarter. Two Sigma Investments LP now owns 24,603 shares of the company's stock worth $122,000 after acquiring an additional 4,231 shares in the last quarter. Jane Street Group LLC increased its position in shares of electroCore by 114.4% during the first quarter. Jane Street Group LLC now owns 36,726 shares of the company's stock worth $246,000 after acquiring an additional 19,599 shares in the last quarter. Cubist Systematic Strategies LLC bought a new stake in shares of electroCore during the first quarter worth $153,000. DRW Securities LLC bought a new stake in shares of electroCore during the fourth quarter worth $264,000. Finally, NewEdge Advisors LLC increased its position in shares of electroCore by 857.9% during the first quarter. NewEdge Advisors LLC now owns 161,955 shares of the company's stock worth $1,083,000 after acquiring an additional 145,047 shares in the last quarter. Institutional investors own 26.74% of the company's stock.

Analyst Ratings Changes

Several equities research analysts have weighed in on ECOR shares. HC Wainwright cut their target price on shares of electroCore from $25.00 to $18.00 and set a "buy" rating on the stock in a report on Monday, January 26th. Weiss Ratings reiterated a "sell (d-)" rating on shares of electroCore in a report on Friday, March 27th. upgraded shares of electroCore to a "strong-buy" rating in a report on Tuesday, February 3rd. Finally, Zacks Research upgraded shares of electroCore from a "strong sell" rating to a "hold" rating in a report on Friday, March 27th. One research analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat, electroCore currently has a consensus rating of "Hold" and an average price target of $18.00.

electroCore Company Profile

electroCore, Inc is a commercial-stage bioelectronic medicine company headquartered in Rockaway, New Jersey. The company specializes in the development and commercialization of non-invasive vagus nerve stimulation (nVNS) therapies designed to address a variety of neurological and inflammatory conditions. Established in 2006, electroCore has focused its efforts on translating neuromodulation science into a compact, patient-administered treatment device.

The company's lead product, gammaCore®, is a handheld, battery-powered device that delivers nVNS through the skin to the cervical branch of the vagus nerve.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.